Cai, Beilei Zhou, Zheng-Yi Xue, Weiguang Hazra, Nisha C Singh, Mukesh Mishra, Dinesh Brixner, Diana Oderda, Gary Biskupiak, Joseph
Published in
Journal of medical economics
To estimate the budget impact of adding capmatinib, the first FDA approved MET inhibitor, to a US commercial or Medicare health plan for patients with metastatic non-small cell lung cancer (mNSCLC) whose tumors have a mutation that leads to MET exon 14 (METex14) skipping. Target population size was estimated using published epidemiology data. Clini...
Hu, Yannan Charaan, Majed van Oostrum, Ilse Heeg, Bart Bell, Timothy
Published in
Journal of medical economics
The clinical efficacy and safety of DAURISMO (glasdegib) combined with low-dose cytarabine (LDAC) were demonstrated in the BRIGHT AML 1003 study among newly diagnosed acute myeloid leukemia patients who are not eligible to receive intensive chemotherapy. This study aims to evaluate its cost-effectiveness versus LDAC alone and azacitidine from a Can...
Brown, C M Richards, K M Vohra, Y Kanu, C Stevens, L Sasane, R Balu, S McAneny, B
Published in
Journal of medical economics
System-level efforts have been deployed to improve oncology care and access while reducing utilization and costs. Understanding the nature of access to care from the perspective of patients themselves is an unmet need. This study examined access to care in a population of women with breast cancer and its relationship to overall patient satisfaction...
Nakhaipour, Hamid Reza Vudumula, Umakanth Khurana, Vivek Sébire, Guillaume Mah, Jean K Pohl, Daniela Schecter, Robyn Adlard, Nicholas
Published in
Journal of medical economics
To evaluate the cost-effectiveness of fingolimod versus interferon (IFN)-β1a at a dose of 30 μg per week for the treatment of relapsing pediatric-onset multiple sclerosis (POMS) in Canada. A discrete-time Markov model was developed to compare fingolimod with IFN β-1a over a time horizon of two years representing patients followed up to mean age of ...
Capri, Stefano Porta, Camillo Condorelli, Claudia Premoli, Eleonora Khare, Ankur Kalra, Manik Modi, Niraj Ratto, Barbara
Published in
Journal of medical economics
To assess the cost-effectiveness of pazopanib versus sunitinib as a first-line treatment for patients with metastatic renal cell carcinoma (mRCC) from an Italian National Health Service perspective, considering the evolving Italian landscape in terms of new reimbursement agreements trend. This analysis is an update of the previously published cost-...
Narayan, Omendra Bentley, Anthony Mowbray, Katie Hermansson, Monika Pivonka, Dominic Kemadjou, Eric Ngonga Belsey, Jonathan
Published in
Journal of medical economics
Respiratory syncytial virus (RSV) is a common cause of respiratory infection in infants and severe infection can result in hospitalization. The passive immunization, palivizumab, is used as prophylaxis against RSV, however, use in the UK is restricted to populations at high risk of hospitalization. This study assesses the cost-effectiveness (CE) of...
Ohno, Shinya Shoji, Ayako Hatake, Kiyohiko Oya, Naoko Igarashi, Ataru
Published in
Journal of medical economics
Obinutuzumab (GA101; G) is a new treatment for follicular lymphoma (FL) that is anticipated to have greater efficacy than the current treatment, rituximab (R). The aim of this study was to evaluate the cost-effectiveness of G plus chemotherapy (G + Chemo) against that of R plus chemotherapy (R + Chemo) for patients in Japan with previously untreate...
Walter, Evelyn Hausberger, Sophie-Christin Groß, Evelyn Siebert, Uwe
Published in
Journal of medical economics
Inflammatory-Bowel-Disease (IBD) is a lifelong illness with significant impact on health-related quality of life (HRQoL). The disease-burden causes work productivity impairment, such as sick-leave and restriction of leisure time activities. From a societal perspective, productivity loss often contributes significantly to the total costs. The aim of...
AlRuthia, Yazed Almadi, Majid Aljebreen, Abdulrahman Azzam, Nahla Alsharif, Wejdan Alrasheed, Hala Almuaythir, Ghadah Saeed, Maria HajkhderMullaissa, Baraa Alharbi, Othman
...
Published in
Journal of medical economics
This study's objectives were to examine and compare the cost-effectiveness of biologic and non-biologic therapies in the improvement of the health-related quality of life (HRQoL) of patients with inflammatory bowel disease (IBD) in Saudi Arabia. This retrospective cohort study analyzed data from the medical records of patients with IBD treated at a...
Timofeyev, Yuriy Jakovljevic, Mihajlo
Published in
Journal of medical economics
Fraud- or theft-related crimes account for the highest number of crimes in the mental health industry in the US. This exploratory study aims to demonstrate a fraudster's and respective victims' profiles as well as to identify the loss predictors' hierarchy in the mental health industry in the US. The Psychiatric Crime database and mixed-effects mod...
